Cibc World Market Inc. Makes New $6.51 Million Investment in Boston Scientific Corporation $BSX

Cibc World Market Inc. bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 152,542 shares of the medical equipment provider’s stock, valued at approximately $6,510,000.

A number of other hedge funds have also made changes to their positions in BSX. Kelleher Financial Advisors bought a new position in shares of Boston Scientific during the second quarter worth about $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific during the first quarter worth $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Up 1.7%

Shares of Boston Scientific stock opened at $49.86 on Wednesday. The business has a fifty day simple moving average of $46.44 and a 200-day simple moving average of $57.14. The firm has a market cap of $72.26 billion, a price-to-earnings ratio of 20.19, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Truist Financial decreased their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Evercore set a $65.00 target price on shares of Boston Scientific in a report on Monday, July 6th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Barclays dropped their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Finally, Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a report on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.